2023 World Conference on Lung Cancer (Posters)-EP08.02. Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer

EP08.02. Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study aimed to examine the effectiveness and safety of durvalumab maintenance therapy for patients with locally advanced non-small cell lung cancer (NSCLC), specifically those with EGFR, ALK, or ROS-1 driver mutations. The study analyzed 141 patients who received definitive chemoradiotherapy at Osaka Toneyama Medical Center in Japan between January 2013 and December 2022. Patients were divided into two categories based on the presence or absence of driver mutations and whether they received durvalumab before or after its approval in Japan.<br /><br />The results showed that durvalumab significantly improved relapse-free survival in patients without EGFR, ALK, or ROS-1 mutations. However, there was no significant benefit in relapse-free survival for patients with these mutations compared to a watchful waiting strategy. It is worth noting that patients with EGFR mutation-positive advanced NSCLC may not respond well to first-line immunotherapy. Therefore, the lack of effectiveness of durvalumab in patients with EGFR mutations can be understood.<br /><br />The study also suggested that NSCLC patients with other driver mutations, such as KRAS and BRAF, who have high PD-L1 expression levels, may benefit from durvalumab in terms of relapse-free survival. However, the data in this study were not sufficient to confirm the benefit of durvalumab in these patients.<br /><br />In conclusion, this research indicates that the efficiency of durvalumab consolidation therapy may be limited for patients with EGFR, ALK, or ROS-1 driver mutations. The use of durvalumab for locally advanced NSCLC with these mutations remains controversial. Further investigation and data accumulation are needed to validate these findings.

Asset Subtitle

Yuki Akazawa

Meta Tag

Speaker Yuki Akazawa

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

durvalumab

maintenance therapy

NSCLC

driver mutations

relapse-free survival

chemoradiotherapy

immunotherapy

KRAS

BRAF

PD-L1 expression levels